Since the experimental design of our protocol consists of the simultaneous administration of CsA and empagliflozin from the beginning of the study, the results obtained suggest that SGLT2 inhibition might have a preventive role against the development of renal diseases that is not restricted, as commonly thought, to diabetic nephropathy. This evidence concerns the gene SLC5A2 and diabetic kidney disease.